Emerging principles in protease-based drug discovery

[1]  Celeste B. Burness,et al.  Dabigatran Etexilate , 2012, Drugs.

[2]  Sukwon Hong,et al.  Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. , 2010, The Biochemical journal.

[3]  K. Gevaert,et al.  MS‐driven protease substrate degradomics , 2010, Proteomics.

[4]  Neil D. Rawlings,et al.  MEROPS: the peptidase database , 2009, Nucleic Acids Res..

[5]  G. Salvesen,et al.  Structural and kinetic determinants of protease substrates , 2009, Nature Structural &Molecular Biology.

[6]  R. Düsing,et al.  ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial , 2009, Current medical research and opinion.

[7]  P. E. Van den Steen,et al.  “Reverse degradomics”, monitoring of proteolytic trimming by multi‐CE and confocal detection of fluorescent substrates and reaction products , 2009, Electrophoresis.

[8]  J. Dalton,et al.  The M17 leucine aminopeptidase of the malaria parasite Plasmodium falciparum: importance of active site metal ions in the binding of substrates and inhibitors. , 2009, Biochemistry.

[9]  C. Craik,et al.  Inhibition of a Viral Enzyme by a Small Molecule Dimer Disruptor , 2009, Nature chemical biology.

[10]  Keith D Wilkinson,et al.  Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. , 2009, Annual review of biochemistry.

[11]  I. Melnikova.  The anticoagulants market , 2009, Nature Reviews Drug Discovery.

[12]  Stephen J. Weiss,et al.  Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited , 2009, The Journal of cell biology.

[13]  Vishva Dixit,et al.  Death receptor signal transducers: nodes of coordination in immune signaling networks , 2009, Nature Immunology.

[14]  Dima Kozakov,et al.  Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..

[15]  Edward F. Chang,et al.  Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. , 2009, Cancer research.

[16]  H. Lijnen,et al.  New insights into the molecular mechanisms of the fibrinolytic system , 2009, Journal of thrombosis and haemostasis : JTH.

[17]  C. Craik,et al.  Positional scanning synthetic combinatorial libraries for substrate profiling. , 2009, Methods in molecular biology.

[18]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.

[19]  K. Sureshkumar.  Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy , 2008, Vascular health and risk management.

[20]  M. Scully,et al.  ADAM proteins - therapeutic potential in cancer. , 2008, Current cancer drug targets.

[21]  J. Mikolajczyk,et al.  Positional-scanning fluorigenic substrate libraries reveal unexpected specificity determinants of DUBs (deubiquitinating enzymes). , 2008, The Biochemical journal.

[22]  K. Garcia,et al.  Small Molecule-Induced Allosteric Activation of the Vibrio cholerae RTX Cysteine Protease Domain , 2008, Science.

[23]  I. Melnikova.  Hepatitis C therapies , 2008, Nature Reviews Drug Discovery.

[24]  An engineered protease that cleaves specifically after sulfated tyrosine. , 2008, Angewandte Chemie.

[25]  Harald Schwalbe,et al.  Perspectives on NMR in drug discovery: a technique comes of age , 2008, Nature Reviews Drug Discovery.

[26]  V. Nizet,et al.  Recent advances in understanding the molecular basis of group B Streptococcus virulence , 2008, Expert Reviews in Molecular Medicine.

[27]  N. Goodey,et al.  Allosteric regulation and catalysis emerge via a common route. , 2008, Nature chemical biology.

[28]  J. McKerrow,et al.  Identification of a new class of nonpeptidic inhibitors of cruzain. , 2008, Journal of the American Chemical Society.

[29]  A. Bell,et al.  Chemical Target Validation Studies of Aminopeptidase in Malaria Parasites Using α-Aminoalkylphosphonate and Phosphonopeptide Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.

[30]  George Georgiou,et al.  Highly active and selective endopeptidases with programmed substrate specificities. , 2008, Nature chemical biology.

[31]  G. Salvesen,et al.  Activation mechanism and substrate specificity of the Drosophila initiator caspase DRONC , 2008, Cell Death and Differentiation.

[32]  H. Brunner,et al.  Aliskiren: the first renin inhibitor for clinical treatment , 2008, Nature Reviews Drug Discovery.

[33]  R. Pike,et al.  The initiating proteases of the complement system: controlling the cleavage. , 2008, Biochimie.

[34]  G. Scapin,et al.  Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines. , 2008, Journal of medicinal chemistry.

[35]  J. Mikolajczyk,et al.  Activity profiling of human deSUMOylating enzymes (SENPs) with synthetic substrates suggests an unexpected specificity of two newly characterized members of the family. , 2007, The Biochemical journal.

[36]  V. Turk,et al.  Selective activity-based probes for cysteine cathepsins. , 2008, Angewandte Chemie.

[37]  J. Joyce,et al.  Cysteine cathepsin proteases as pharmacological targets in cancer. , 2008, Trends in pharmacological sciences.

[38]  J. Dalton,et al.  Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds. , 2007, Journal of medicinal chemistry.

[39]  C. López-Otín,et al.  Emerging roles of proteases in tumour suppression , 2007, Nature Reviews Cancer.

[40]  Ze'ev Ronai,et al.  Small Ubiquitin-related Modifier (SUMO)-specific Proteases , 2007, Journal of Biological Chemistry.

[41]  D. Fairlie,et al.  A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. , 2007, Drug discovery today.

[42]  T. Renné,et al.  Role of Factor XII in hemostasis and thrombosis: clinical implications , 2007, Expert review of cardiovascular therapy.

[43]  Jialiang Hu,et al.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases , 2007, Nature Reviews Drug Discovery.

[44]  Andreas Plückthun,et al.  Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. , 2007, Structure.

[45]  N. Thornberry,et al.  Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin , 2007, Clinical pharmacology and therapeutics.

[46]  G. Spraggon,et al.  Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode. , 2007, Journal of medicinal chemistry.

[47]  G. Salvesen,et al.  The apoptosome: signalling platform of cell death , 2007, Nature Reviews Molecular Cell Biology.

[48]  G. Lip,et al.  Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X. , 2007, Current opinion in investigational drugs.

[49]  N. Thornberry,et al.  Discovery of JANUVIA TM (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes. , 2007 .

[50]  A. Bell,et al.  Characterization of the Plasmodium falciparum M17 Leucyl Aminopeptidase , 2007, Journal of Biological Chemistry.

[51]  B. Cauwe,et al.  The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases , 2007, Critical reviews in biochemistry and molecular biology.

[52]  S. Brennan.  Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise? , 2006, European Respiratory Journal.

[53]  N. Thornberry,et al.  Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2007, Current topics in medicinal chemistry.

[54]  G. Salvesen,et al.  Caspase substrates , 2007, Cell Death and Differentiation.

[55]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[56]  Jun O. Liu,et al.  Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity , 2006, Proceedings of the National Academy of Sciences.

[57]  B. Turk.  Targeting proteases: successes, failures and future prospects , 2006, Nature Reviews Drug Discovery.

[58]  J. Levy,et al.  The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema , 2006, Expert opinion on investigational drugs.

[59]  A. D'arcy,et al.  Structural Basis of Ubiquitin Recognition by the Deubiquitinating Protease USP2 , 2006, Structure.

[60]  G. Salvesen,et al.  Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family , 2006, EMBO reports.

[61]  M. Scholle,et al.  Mapping Protease Substrates by Using a Biotinylated Phage Substrate Library , 2006, Chembiochem : a European journal of chemical biology.

[62]  Francesco Leonetti,et al.  Substrate Profiling of Cysteine Proteases Using a Combinatorial Peptide Library Identifies Functionally Unique Specificities* , 2006, Journal of Biological Chemistry.

[63]  G. Petsko,et al.  Multiple solvent crystal structures: probing binding sites, plasticity and hydration. , 2006, Journal of molecular biology.

[64]  M. Whitlow,et al.  Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. , 2006, Cancer research.

[65]  L. Cantley,et al.  MMP-20 is predominately a tooth-specific enzyme with a deep catalytic pocket that hydrolyzes type V collagen. , 2006, Biochemistry.

[66]  Xiaodong Cheng,et al.  The Ubiquitin Binding Domain ZnF UBP Recognizes the C-Terminal Diglycine Motif of Unanchored Ubiquitin , 2006, Cell.

[67]  C. Overall,et al.  Towards third generation matrix metalloproteinase inhibitors for cancer therapy , 2006, British Journal of Cancer.

[68]  Christopher M. Overall,et al.  Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer , 2006, Cancer and Metastasis Reviews.

[69]  J. Peters,et al.  Methods to measure ubiquitin-dependent proteolysis mediated by the anaphase-promoting complex. , 2006, Methods.

[70]  P. Andreasen,et al.  A Urokinase-type Plasminogen Activator-inhibiting Cyclic Peptide with an Unusual P2 Residue and an Extended Protease Binding Surface Demonstrates New Modalities for Enzyme Inhibition* , 2005, Journal of Biological Chemistry.

[71]  J. Ellman,et al.  Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. , 2005, Journal of the American Chemical Society.

[72]  Robert A Copeland,et al.  An inhibitor binding pocket distinct from the catalytic active site on human beta-APP cleaving enzyme. , 2005, Biochemistry.

[73]  P. E. Van den Steen,et al.  Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. , 2005, Biochemical pharmacology.

[74]  Jennifer L. Harris,et al.  Functional Profiling of Recombinant NS3 Proteases from All Four Serotypes of Dengue Virus Using Tetrapeptide and Octapeptide Substrate Libraries*[boxs] , 2005, Journal of Biological Chemistry.

[75]  Dawoon Jung,et al.  Efficient synthetic inhibitors of anthrax lethal factor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[76]  P. E. Van den Steen,et al.  Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform. , 2005, Analytical chemistry.

[77]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[78]  S. Krishnaswamy.  Exosite‐driven substrate specificity and function in coagulation , 2005, Journal of thrombosis and haemostasis : JTH.

[79]  G. Salvesen,et al.  The protein structures that shape caspase activity, specificity, activation and inhibition. , 2004, The Biochemical journal.

[80]  J. Potempa,et al.  Activation of the kallikrein-kinin system and release of new kinins through alternative cleavage of kininogens by microbial and human cell proteinases , 2004, Biological chemistry.

[81]  D. Kirchhofer,et al.  Inhibitors of Tissue Factor. Factor VIIa for anticoagulant therapy. , 2004, Current medicinal chemistry.

[82]  J. Wells,et al.  Discovery of an allosteric site in the caspases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[83]  A. Weber.  Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. , 2004, Journal of medicinal chemistry.

[84]  David Reverter,et al.  A basis for SUMO protease specificity provided by analysis of human Senp2 and a Senp2-SUMO complex. , 2004, Structure.

[85]  C. K. Wada.  The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories. , 2004, Current topics in medicinal chemistry.

[86]  A. Lombardi,et al.  The Occasional Venous Thromboses Seen in Patients with Severe (Homozygous) FXII Deficiency are Probably Due to Associated Risk Factors: A Study of Prevalence in 21 Patients and Review of the Literature , 2004, Journal of Thrombosis and Thrombolysis.

[87]  J. Adams,et al.  Development of the Proteasome Inhibitor Velcade™ (Bortezomib) , 2004, Cancer investigation.

[88]  Clemencia Pinilla,et al.  Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. , 2004, Cancer cell.

[89]  Lewis C Cantley,et al.  The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor , 2004, Nature Structural &Molecular Biology.

[90]  J. Gallant.  Tipranavir. , 2020, Drugs.

[91]  E. Davie,et al.  A Brief Historical Review of the Waterfall/Cascade of Blood Coagulation , 2003, Journal of Biological Chemistry.

[92]  Scott A. Erickson,et al.  Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. , 2003, Cancer research.

[93]  Peter Friedl,et al.  Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. , 2003, Blood.

[94]  Peter T Lansbury,et al.  Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. , 2003, Chemistry & biology.

[95]  C. Craik,et al.  Engineering of a macromolecular scaffold to develop specific protease inhibitors , 2003, Nature Biotechnology.

[96]  J. Vane,et al.  The Discovery of Captopril , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[97]  C. Craik,et al.  Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. , 2003, The Biochemical journal.

[98]  C. Craik,et al.  Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. , 2003, Biochemistry.

[99]  W. Delano,et al.  In situ assembly of enzyme inhibitors using extended tethering , 2003, Nature Biotechnology.

[100]  F. Tanaka.  Catalytic antibodies as designer proteases and esterases. , 2002, Chemical reviews.

[101]  B. Furie,et al.  Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse , 2002, Nature Medicine.

[102]  G. Salvesen,et al.  Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. , 2002, Current pharmaceutical design.

[103]  G. Salvesen,et al.  Caspases on the brain , 2002, Journal of neuroscience research.

[104]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[105]  R. Huber,et al.  The methyl group of N(alpha)(Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage. , 2002, Journal of molecular biology.

[106]  Pauline M. Rudd,et al.  Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9) , 2002, Critical reviews in biochemistry and molecular biology.

[107]  J. Whisstock,et al.  The Serpins Are an Expanding Superfamily of Structurally Similar but Functionally Diverse Proteins , 2001, The Journal of Biological Chemistry.

[108]  L. Cantley,et al.  Determination of protease cleavage site motifs using mixture-based oriented peptide libraries , 2001, Nature Biotechnology.

[109]  C. Hashimoto,et al.  Activation of a protease cascade involved in patterning the Drosophila embryo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[110]  Kim Nasmyth,et al.  Cleavage of Cohesin by the CD Clan Protease Separin Triggers Anaphase in Yeast , 2000, Cell.

[111]  K. Goa,et al.  Desirudin: a review of its use in the management of thrombotic disorders. , 2000, Drugs.

[112]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[113]  P. Walsh,et al.  Thrombin-mediated Feedback Activation of Factor XI on the Activated Platelet Surface Is Preferred over Contact Activation by Factor XIIa or Factor XIa* , 2000, The Journal of Biological Chemistry.

[114]  C. Craik,et al.  Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[115]  Francesco Leonetti,et al.  Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin , 2000, Nature Biotechnology.

[116]  J. McKerrow,et al.  Cysteine protease inhibitors as chemotherapy for parasitic infections. , 1999, Bioorganic & medicinal chemistry.

[117]  N. Thornberry,et al.  A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B , 1997, The Journal of Biological Chemistry.

[118]  K. Kario,et al.  Development of Argatroban, a Direct Thrombin Inhibitor, and Its Clinical Application , 1997, Seminars in thrombosis and hemostasis.

[119]  N. Thornberry,et al.  A combinatorial approach for determining protease specificities: application to interleukin-1beta converting enzyme (ICE). , 1997, Chemistry & biology.

[120]  Jonathan A. Ellman,et al.  Synthesis and Applications of Small Molecule Libraries. , 1996, Chemical reviews.

[121]  M. Dennis,et al.  Potent and Selective Kunitz Domain Inhibitors of Plasma Kallikrein Designed by Phage Display (*) , 1995, The Journal of Biological Chemistry.

[122]  J. Wells,et al.  Substrate phage: selection of protease substrates by monovalent phage display. , 1993, Science.

[123]  J. Clozel,et al.  Discovery of remikiren as the first orally active renin inhibitor. , 1993, Arzneimittel-Forschung.

[124]  R. Huber,et al.  The structure of a complex of recombinant hirudin and human alpha-thrombin. , 1990, Science.

[125]  M. Szelke,et al.  Potent new inhibitors of human renin , 1982, Nature.

[126]  J Salvage,et al.  A matter of life and death. , 1981, Nursing times.

[127]  K. Fujikawa,et al.  Basic mechanisms in blood coagulation. , 1975, Annual review of biochemistry.

[128]  B. Bennett,et al.  The normal coagulation mechanism. , 1972, The Medical clinics of North America.

[129]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[130]  J. Peden,et al.  Use of the plasma thrombin time to assess the adequacy of in vivo neutralization of heparin: comparative studies following operations employing extracorporeal circulation. , 1959, Blood.